Clinical Support, Not Recreation, Changed Huberman’s View of Psychedelics

Andrew Huberman does not describe a conversion from skepticism to advocacy. He describes a working model drawn from his own clinically supported experiences: different compounds made different kinds of psychological work possible, while a guide helped determine whether and how to enter difficult territory.

That distinction is rooted in his history. As a teenager, Huberman took LSD and psilocybin recreationally, without considering long-term consequences. He says he did not experience lasting effects, but had enough bad trips to become “very, very cautious, almost paranoid” about psychedelics for years. A bad trip, in his account, was being “in the pit for hours and hours” without a guide, at an age when he characterizes the brain as especially plastic.

His later experiences did not erase that caution. He calls these substances “immensely powerful” and “immensely precarious,” and treats support as a condition of the work he found useful. For Huberman, a trained guide is not simply someone present in the room; the guide can help identify material that may be worth approaching and, at times, say not to go there.

Huberman explicitly rejects recreational use for people like himself and warns against people running out to take these substances without clinical support. Young people and others for whom the usual cautions apply should not take them, he says. His claim is not that a drug combination should work for others. It is that important psychological material can remain inaccessible even to someone who wants to address it.

Andrew Huberman used MDMA in four clinically supported sessions, separated by months or roughly a year, with talk therapy before, during, and afterward. He describes the experience as helping him feel emotions and recognize what a whole-body feeling was about.

He calls MDMA an empathogen rather than a psychedelic. It raises dopamine and serotonin simultaneously, he says, as well as oxytocin dramatically. But he notes that data do not simply credit oxytocin for MDMA’s empathogenic clinical effects: giving oxytocin alone does not produce the same result. The combined effects may matter, he says.

What Huberman found most useful was not a desire to dance or have sex, but an ability to remain with difficult material. MDMA gave him a sense that he could hold himself as a friend. At the same time, he says, it can make nearly any object of attention seem full of peace, love, or importance. A person can get pulled into a “forcefield” around something that no longer feels consequential after the session. That is another reason he emphasizes a trained guide.

Psilocybin, by contrast, was dark and harrowing for him. Huberman describes taking four to five grams of dried psilocybe mushrooms and experiencing purging and vomiting partway through. Being on psilocybin alone was terrifying, he says. Yet psilocybin also proved unusually effective at revealing the structure of his thinking.

His mind tends to organize experience through analogies, so his insights arrived as symbolic representations. Someone else might encounter comparable insights through music or bodily sensation, he suggests. What mattered was not the form of the insight but that previously implicit patterns became visible.

One example was what he calls “self-seduction”: becoming enchanted by the promise of a future outcome that is not realistic. He came to recognize multiple versions of that pattern in his own life. Once visible, he says, the pattern could not be unseen. Journaling and taking notes after the drug had worn off helped turn the session’s impressions into a more durable understanding of what was serving him and what was not.

Andrew Huberman describes two sessions in which he took MDMA and, a couple of hours later, high-dose psilocybin. He calls the resulting work the hardest he has done, despite substantial prior therapy, journaling, and separate experiences with both compounds.

The combination mattered, in his account, because the compounds supplied contrasting conditions. Psilocybin brought him toward material he found frightening; MDMA gave him the feeling that he could endure it without treating himself as an enemy. During one session, he sensed difficult work approaching and initially wanted to avoid it. He could have spent the session listening to music, he says, but chose instead to move toward what emerged.

What emerged was not simply painful events from childhood and later life, including some he says were self-inflicted and some were not. It was “all the things that didn’t happen”—things he wished had happened but was not in a position to create for himself at the time.

That distinction gives the experience its practical weight. Huberman says no therapist had directly proposed that question to him, and that even if one had, he might not have been able to access the full emotional experience of the absence. Conventional therapy, journaling, time, MDMA, and psilocybin taken separately had helped him reach some peace with hard experiences. But the combined session brought him into what he describes as the full emotional experience of what was missing.

The session was “heavy” and “gnarly,” but it produced direction rather than simply catharsis. The things that had been absent became things he believed he could now create. He says he left with clearer aims and subsequently began making changes in his daily life to move in those directions.

Tim Ferriss suggests that access to underlying material may itself limit conventional therapy. Andrew Huberman answers that neuroplasticity is the goal, but it must be directed. A therapeutic target may not be identifiable in advance—not only because someone cannot name a trauma, but because they may not recognize an absence as something that can be explored.

The supported sessions, as Huberman describes them, revealed what needed attention and let him engage much of it in real time. But he does not present the altered state itself as the outcome. He emphasizes reflection after the drug had worn off, including journaling, and the value of leaving with a clear mission for ordinary life.

Huberman also reports that adding psilocybin to MDMA avoided the two-day downturn he otherwise associated with MDMA. Rather than feeling cratered afterward, he says he had productive workweeks and strong workouts. But he does not generalize from that result or present polypharmacology as the answer. In this case, he says, it was the appropriate tool for him.

More than a year after the difficult combined session, Huberman says its orientation has endured. The lasting value he assigns to the experience is not intensity. It is the ability to identify what needs to be built, then begin building it.